## Gene Summary
MAPK1 (Mitogen-Activated Protein Kinase 1), also known as ERK2 (Extracellular Signal-Regulated Kinase 2), is a crucial component of the MAP kinase signal transduction pathway. It plays a significant role in various cellular processes including proliferation, differentiation, and response to stress. MAPK1 is activated by various extracellular stimuli such as growth factors and cytokines through a protein kinase cascade, resulting in its phosphorylation. It is ubiquitously expressed in various tissues and regulates gene expression by phosphorylating a number of transcription factors.

## Gene Drugs, Diseases, Phenotypes, and Pathways
MAPK1 is involved in several key signaling pathways besides the MAP kinase/ERK pathway, including the regulation of the cell cycle, apoptosis, and cell morphology. Its dysregulation is linked to various diseases, particularly cancer. For instance, overactivation of MAPK1 has been observed in numerous cancers, aiding in tumor growth and metastasis. Furthermore, MAPK1 interacts with pathological signaling in neurodegenerative diseases like Alzheimerâ€™s disease. Given its widespread role in critical cellular functions and pathological conditions, MAPK1 is seen as a potential therapeutic target in these diseases.

## Pharmacogenetics
The pharmacogenetics of MAPK1 primarily comes into play in the context of cancer treatment. Drugs targeting the MAPK/ERK pathway aim to inhibit overactive signaling that often leads to cancer progression. Some of these inhibitors include Cobimetinib and Trametinib, both used in the treatment of melanoma, among other cancers. These drugs specifically target downstream components of the pathway activated by MAPK1 and demonstrate how alterations in MAPK1 signaling influence therapeutic responses. Thus, understanding the pharmacogenetics of MAPK1 can significantly enhance the efficacy and specificity of treatment regimens involving these inhibitors in cancer therapy.